Applied Molecular Transport Inc. (AMTI): Price and Financial Metrics
GET POWR RATINGS... FREE!
AMTI Stock Price Chart Interactive Chart >
AMTI Price/Volume Stats
| Current price | $0.63 | 52-week high | $10.42 |
| Prev. close | $0.61 | 52-week low | $0.33 |
| Day low | $0.62 | Volume | 96,081 |
| Day high | $0.66 | Avg. volume | 205,324 |
| 50-day MA | $0.80 | Dividend yield | N/A |
| 200-day MA | $1.95 | Market Cap | 24.53M |
Applied Molecular Transport Inc. (AMTI) Company Bio
Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood and Randall J. Mrsny on November 21, 2016 and is headquartered in South San Francisco, CA.
Latest AMTI News From Around the Web
Below are the latest news stories about APPLIED MOLECULAR TRANSPORT INC that investors may wish to consider to help them evaluate AMTI as an investment opportunity.
Should This Make Applied Molecular Transport Inc. (NASDAQ: AMTI) Investors Worry?The trading price of Applied Molecular Transport Inc. (NASDAQ:AMTI) closed lower on Tuesday, December 27, closing at $0.37, -14.11% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $0.36 and $0.4495. In examining the 52-week price action we see that the stock hit a … Should This Make Applied Molecular Transport Inc. (NASDAQ: AMTI) Investors Worry? Read More » |
Applied Molecular Transport Inc. (AMTI) can beat the pack with these strategiesAs of Friday, Applied Molecular Transport Inc.’s (NASDAQ:AMTI) stock closed at $0.44, down from $1.03 the previous day. While Applied Molecular Transport Inc. has underperformed by -57.77%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AMTI fell by -97.01%, with highs and lows ranging from $14.94 […] |
AMTI stock drops as JMP downgrades on trial setback (NASDAQ:AMTI)Applied Molecular Transport (AMTI) lost ~16% pre-market Friday after JMP Securities downgraded it to Market Perform citing a clinical trial setback. Read the full story here. |
Applied Molecular's Ulcerative Colitis Candidate Fails To Separate From Placebo In Untreated PatientsApplied Molecular Transport Inc (NASDAQ: AMTI) announced topline Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naïve and experienced patients with moderate-to-severe ulcerative colitis (UC). The clinical remission (CR) rate in patients treated with AMT-101 monotherapy was 17.1% (12/70 patients) compared to a CR rate of 20.0% (7/35 patients) with placebo, which was above the company's baseline assumption for placebo CR rates based on published data in moderate-to-seve |
Stocks to Watch: iMedia Brands, Centogene, Applied Molecular TransportBy Denny Jacob iMedia Brands Inc. said it is selling three buildings for $48 million to reduce its debt position. Shares surged 26% in after-hours trading…. |
AMTI Price Returns
| 1-mo | 50.00% |
| 3-mo | -28.25% |
| 6-mo | -67.36% |
| 1-year | -93.31% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 50.00% |
| 2022 | -97.00% |
| 2021 | -54.57% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...